Final Results of a Phase I/II Trial of the Combination Bendamustine and Rituximab With Temsirolimus (BeRT) in Relapsed Mantle Cell Lymphoma and Follicular Lymphoma

In this phase I/II study, we explored the combination of Temsirolimus with Bendamustine and Rituximab (BeRT) in patients with relapsed or refractory (r/r) follicular lymphoma (FL) or mantle cell lymphoma (MCL). Patients with 1 to 3 previous therapies received Bendamustine (90 mg/m(2), day 1 + 2) and...

Descripción completa

Detalles Bibliográficos
Autores principales: Hess, Georg, Wagner, Karola, Keller, Ulrich, La Rosee, Paul, Atta, Johannes, Hübel, Kai, Lerchenmueller, Christian, Schoendube, Daniel, Witzens-Harig, Mathias, Ruckes, Christian, Medler, Christoph, van Oordt, Christina, Klapper, Wolfram, Theobald, Matthias, Dreyling, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7306311/
https://www.ncbi.nlm.nih.gov/pubmed/32647802
http://dx.doi.org/10.1097/HS9.0000000000000398

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7306311/
https://www.ncbi.nlm.nih.gov/pubmed/32647802
http://dx.doi.org/10.1097/HS9.0000000000000398

Ejemplares similares